ReviewAnnals of gastroenterological surgery2018
p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma.
Review in Annals of gastroenterological surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 48 citations in OpenAlex.
- Epidemiological risk factors and inferred p53 pathway dysregulation in Esophageal squamous cell carcinoma in the Somali population.Discover oncology · 2026Review
- Prognostic and diagnostic significance of serum p53 antibody levels in patients with surgically treated pancreatic cancer.Oncology letters · 2026Article
- Impact of High Immunoreactivity on Surgically Treated Serum p53 Antibody-Positive Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy: A Multi-Institutional Study of 637 Cases.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2026Article
- Computational Approach Improves Diagnostic Performance Based on Tumor-Associated Autoantibodies in Esophageal Squamous Cell Carcinoma.Computational and structural biotechnology journal · 2026Article
- Mutant p53 and TP53 mutations in esophageal squamous cell carcinoma: consistency and diagnostic significance.Frontiers in genetics · 2026Article
- Evaluating serum extra spindle pole bodies-like 1 proteinWorld journal of hepatology · 2025Article
- Prognostic significance of six autoantibodies in esophageal squamous cell carcinoma: A prospective multi-institutional study.Annals of gastroenterological surgery · 2025Article
- Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.British journal of cancer · 2024Observational
- Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer.Annals of gastroenterological surgery · 2024Article
- Decoding SEC24 Homolog D, COPII coat complex component accuracy as a signature gene in three human cancers.American journal of cancer research · 2023Article
- Comparison between a new assay system, ElecsysMolecular and clinical oncology · 2022Article
- Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer.Molecular and clinical oncology · 2022Article
- Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers.International journal of clinical oncology · 2022Article
- Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer.Frontiers in genetics · 2022Article
- Gastrointestinal and Pancratohepatobiliary Cancers: A Comprehensive Review on Epidemiology and Risk Factors Worldwide.Middle East journal of digestive diseases · 2022Review
- Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke.BMC medicine · 2021Article
- Urinary microRNA biomarkers for detecting the presence of esophageal cancer.Scientific reports · 2021Article
- High Expression of MDM2 and the p53 Protein is Predictive Biomarkers for Poor Prognosis of Oesophageal Squamous Cell Carcinoma.Cancer management and research · 2021Article
- Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.Frontiers in oncology · 2021Article
- Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma: a multi-institutional study.Esophagus : official journal of the Japan Esophageal Society · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We reviewed our research concerning p53 molecules in esophageal squamous cell carcinoma by focusing on the p53 molecular diagnosis and treatment of esophageal squamous cell carcinoma. First, we developed diagnostic tools to analyze serum p53 autoantibodies to detect esophageal squamous cell carcinoma. Positive rate was around 25% to 30% in all patients and around 20% even in stage I patients. Presence of serum p53 antibodies was significantly associated with overexpression of p53 protein in tumor cells. Seropositive patients were more likely than seronegative patients to be resistant to chemotherapy. Monitoring of the titer of serum p53 autoantibodies was useful in predicting patients at high risk of recurrence and/or treatment response. Second, using Ad5CMV-p53 for 10 patients with advanced esophageal squamous cell carcinoma, we carried out a phase I/II study of adenoviral-mediated p53 gene therapy. Although no complete response was observed, local tumor was stabilized in nine patients. No serious adverse events related to Ad5CMV-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.